A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
研究概览
详细说明
研究类型
注册
阶段
- 阶段1
联系人和位置
学习地点
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- National Cancer Institute (NCI)
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
Patients with a histologic diagnosis confirmed from a pretreatment biopsy at the Laboratory of Pathology, NCI of one of the following entities: Diffuse small Lymphocytic Lymphoma; Follicular, Small Cleaved cell Lymphoma; Follicular, Mixed Small Cleaved and Large Cell Lymphoma; Follicular Large Cell Lymphoma; Diffuse, Intermediately Differentiated Lymphocytic Lymphoma; Diffuse, Small Cleaved Cell Lymphoma; Diffuse, Mixed Small and Large Cell Lymphoma; Diffuse, Large Cell Lymphoma; Large Cell Immunoblastic Lymphoma; Small Noncleaved Cell Lymphoma.
Presence of CD22 antigen on at least 30 percent of tumor cells.
Presence of objectively measurable sites of disease. Bone marrow positivity and circulating tumor cells in the peripheral blood will be considered evaluable but not measurable disease.
No patients with purely B-cell Lymphosarcoma cell leukemia without nodal or soft tissue involvement.
No patients with B-cell chronic lymphocytic leukemia, or B-cell or pre-B-cell acute lymphocytic leukemia, and hairy cell leukemia.
Patients with objectively measurable disease outside a radiation port or disease which has clearly progressed within a radiation port.
HIV negative.
No CNS disease.
No pulmonary parenchymal disease.
Pleural effusions or ascites may be present.
Patients with progression of disease despite at least one standard combination chemotherapy regimen.
No chemotherapy for at least two weeks prior to entry.
Patients who do not desire or are not candidates for autologous or allogeneic bone marrow transplantation procedures.
Life expectancy of at least 3 months
Creatinine clearance greater than 60 cc per minute.
Total bilirubin less than 1.5 mg/dl.
SGPT less than 2 times the upper limit of normal.
Albumin greater than 75 percent of the lower limit of normal.
If prior treatment with doxorubicin, the radionuclide or echocardiogram ejection fraction shall be at least 35 percent.
Performance status 0-2.
Not in need of current radiation therapy to alleviate local problems.
No prior exposure to murine antibodies.
No need for current corticosteroid treatment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
合作者和调查者
出版物和有用的链接
一般刊物
- Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW. Redesigning nature's poisons to create anti-tumor reagents. Science. 1987 Nov 20;238(4830):1098-104. doi: 10.1126/science.3317828.
- Thorpe PE, Detre SI, Foxwell BM, Brown AN, Skilleter DN, Wilson G, Forrester JA, Stirpe F. Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution. Eur J Biochem. 1985 Feb 15;147(1):197-206. doi: 10.1111/j.1432-1033.1985.tb08737.x.
- Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW, et al. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer. 1988 Nov 15;42(5):792-7. doi: 10.1002/ijc.2910420527.
研究记录日期
研究主要日期
学习开始
初级完成
研究完成
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.